{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T21:39:26Z","timestamp":1790199566925,"version":"4.1.0"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2022,5,7]],"date-time":"2022-05-07T00:00:00Z","timestamp":1651881600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,5,7]],"date-time":"2022-05-07T00:00:00Z","timestamp":1651881600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100005230","name":"Natural Science Foundation of Chongqing","doi-asserted-by":"publisher","award":["cstc2018jcyjAX0260"],"award-info":[{"award-number":["cstc2018jcyjAX0260"]}],"id":[{"id":"10.13039\/501100005230","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Rheumatol"],"published-print":{"date-parts":[[2022,8]]},"DOI":"10.1007\/s10067-022-06155-6","type":"journal-article","created":{"date-parts":[[2022,5,7]],"date-time":"2022-05-07T15:02:37Z","timestamp":1651935757000},"page":"2561-2569","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Response to belimumab in thrombotic thrombocytopenic purpura associated with systemic lupus erythematosus: a case-based review"],"prefix":"10.1007","volume":"41","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7635-9114","authenticated-orcid":false,"given":"Shen-ju","family":"Liang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2476-1421","authenticated-orcid":false,"given":"Quan-you","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3254-3467","authenticated-orcid":false,"given":"Meng-Shan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2747-3532","authenticated-orcid":false,"given":"Ming-Ye","family":"Lv","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8232-9421","authenticated-orcid":false,"given":"Wen-Ting","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4372-3324","authenticated-orcid":false,"given":"Yi","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,5,7]]},"reference":[{"key":"6155_CR1","doi-asserted-by":"publisher","first-page":"2836","DOI":"10.1182\/blood-2016-10-709857","volume":"129","author":"BS Joly","year":"2017","unstructured":"Joly BS, Coppo P, Veyradier A (2017) Thrombotic thrombocytopenic purpura. Blood 129:2836\u20132846. https:\/\/doi.org\/10.1182\/blood-2016-10-709857","journal-title":"Blood"},{"key":"6155_CR2","doi-asserted-by":"publisher","first-page":"e23","DOI":"10.1056\/NEJMicm1813768","volume":"380","author":"S Bhandari","year":"2019","unstructured":"Bhandari S, Kumar R (2019) Thrombotic thrombocytopenic purpura. N Engl J Med 380:e23. https:\/\/doi.org\/10.1056\/NEJMicm1813768","journal-title":"N Engl J Med"},{"key":"6155_CR3","doi-asserted-by":"publisher","first-page":"757192","DOI":"10.3389\/fimmu.2021.757192","volume":"12","author":"A Laghmouchi","year":"2021","unstructured":"Laghmouchi A, Graca N, Voorberg J (2021) Emerging concepts in immune thrombotic thrombocytopenic purpura. Front Immunol 12:757192. https:\/\/doi.org\/10.3389\/fimmu.2021.757192","journal-title":"Front Immunol"},{"key":"6155_CR4","doi-asserted-by":"publisher","first-page":"2332","DOI":"10.1016\/S0140-6736(19)30237-5","volume":"393","author":"L Durcan","year":"2019","unstructured":"Durcan L, O\u2019Dwyer T, Petri M (2019) Management strategies and future directions for systemic lupus erythematosus in adults. Lancet 393:2332\u20132343. https:\/\/doi.org\/10.1016\/S0140-6736(19)30237-5","journal-title":"Lancet"},{"key":"6155_CR5","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1093\/rheumatology\/ken510","volume":"48","author":"P Letchumanan","year":"2009","unstructured":"Letchumanan P, Ng HJ, Lee LH, Thumboo JA (2009) Comparison of thrombotic thrombocytopenic purpura in an inception cohort of patients with and without systemic lupus erythematosus. Rheumatology (Oxford) 48:399\u2013403. https:\/\/doi.org\/10.1093\/rheumatology\/ken510","journal-title":"Rheumatology (Oxford)"},{"key":"6155_CR6","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1177\/0961203308094360","volume":"18","author":"SK Kwok","year":"2009","unstructured":"Kwok SK, Ju JH, Cho CS, Kim HY, Park SH (2009) Thrombotic thrombocytopenic purpura in systemic lupus erythematosus: risk factors and clinical outcome: a single centre study. Lupus 18:16\u201321. https:\/\/doi.org\/10.1177\/0961203308094360","journal-title":"Lupus"},{"key":"6155_CR7","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1186\/s13023-020-01510-9","volume":"15","author":"C Yue","year":"2020","unstructured":"Yue C, Su J, Fan X, Song L, Jiang W, Xia J, Shi T, Zhang X, Li X (2020) Immune-mediated thrombotic thrombocytopenic purpura in patients with and without systemic lupus erythematosus: a retrospective study. Orphanet J Rare Dis 15:225. https:\/\/doi.org\/10.1186\/s13023-020-01510-9","journal-title":"Orphanet J Rare Dis"},{"key":"6155_CR8","doi-asserted-by":"publisher","first-page":"782","DOI":"10.12659\/ajcr.898955","volume":"17","author":"M Abu-Hishmeh","year":"2016","unstructured":"Abu-Hishmeh M, Sattar A, Zarlasht F, Ramadan M, Abdel-Rahman A, Hinson S, Hwang C (2016) Systemic lupus erythematosus presenting as refractory thrombotic thrombocytopenic purpura: a diagnostic and management challenge. A case report and concise review of the literature. Am J Case Rep 17:782\u2013787. https:\/\/doi.org\/10.12659\/ajcr.898955","journal-title":"Am J Case Rep"},{"key":"6155_CR9","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1186\/s13052-019-0641-y","volume":"45","author":"J Li","year":"2019","unstructured":"Li J, Jiang JJ, Wang CY, Jian S, Zhou Y, Ma MS, Tang XY, Wang L, Quan MY, Zhang Y, Xiao J, He YY, Song HM (2019) Clinical features and prognosis of patients with thrombotic thrombocytopenic purpura associated with systemic lupus erythematosus: a review of 25 cases. Ital J Pediatr 45:55. https:\/\/doi.org\/10.1186\/s13052-019-0641-y","journal-title":"Ital J Pediatr"},{"key":"6155_CR10","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1182\/blood.2019000954","volume":"134","author":"MA Mazepa","year":"2019","unstructured":"Mazepa MA, Masias C, Chaturvedi S (2019) How targeted therapy disrupts the treatment paradigm for acquired TTP: the risks, benefits, and unknowns. Blood 134:415\u2013420. https:\/\/doi.org\/10.1182\/blood.2019000954","journal-title":"Blood"},{"key":"6155_CR11","doi-asserted-by":"publisher","first-page":"1961","DOI":"10.1177\/0961203320953473","volume":"29","author":"W Ma","year":"2020","unstructured":"Ma W, Bai W, Wu X, Zhao J, Li M, Zeng X (2020) Successful treatment of refractory thrombotic thrombocytopenic purpura associated with systemic lupus erythematosus with combination of plasma exchange and low-dose rituximab. Lupus 29:1961\u20131967. https:\/\/doi.org\/10.1177\/0961203320953473","journal-title":"Lupus"},{"key":"6155_CR12","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1056\/NEJMoa1806311","volume":"380","author":"M Scully","year":"2019","unstructured":"Scully M, Cataland SR, Peyvandi F, Coppo P, Knobl P, Kremer HJ, Metjian A, de la Rubia J, Pavenski K, Callewaert F, Biswas D, De Winter H, Zeldin RK (2019) Caplacizumab treatment for acquired thrombotic thrombocytopenic purpura. N Engl J Med 380:335\u2013346. https:\/\/doi.org\/10.1056\/NEJMoa1806311","journal-title":"N Engl J Med"},{"key":"6155_CR13","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1182\/blood.2020008021","volume":"137","author":"P Coppo","year":"2021","unstructured":"Coppo P, Bubenheim M, Azoulay E, Galicier L, Malot S, Bige N, Poullin P, Provot F, Martis N, Presne C, Moranne O, Benainous R, Dossier A, Seguin A, Hie M, Wynckel A, Delmas Y, Augusto JF, Perez P, Rieu V, Barbet C, Lhote F, Ulrich M, Rumpler AC, de Witte S, Krummel T, Veyradier A, Benhamou Y (2021) A regimen with caplacizumab, immunosuppression, and plasma exchange prevents unfavorable outcomes in immune-mediated TTP. Blood 137:733\u2013742. https:\/\/doi.org\/10.1182\/blood.2020008021","journal-title":"Blood"},{"key":"6155_CR14","doi-asserted-by":"publisher","first-page":"102736","DOI":"10.1016\/j.autrev.2020.102736","volume":"20","author":"T Mockel","year":"2021","unstructured":"Mockel T, Basta F, Weinmann-Menke J, Schwarting A (2021) B cell activating factor (BAFF): structure, functions, autoimmunity and clinical implications in systemic lupus erythematosus (SLE). Autoimmun Rev 20:102736. https:\/\/doi.org\/10.1016\/j.autrev.2020.102736","journal-title":"Autoimmun Rev"},{"key":"6155_CR15","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1007\/s40265-018-0872-z","volume":"78","author":"HA Blair","year":"2018","unstructured":"Blair HA, Duggan ST (2018) Belimumab: a review in systemic lupus erythematosus. Drugs 78:355\u2013366. https:\/\/doi.org\/10.1007\/s40265-018-0872-z","journal-title":"Drugs"},{"key":"6155_CR16","doi-asserted-by":"publisher","first-page":"16039","DOI":"10.1038\/nrdp.2016.39","volume":"2","author":"A Kaul","year":"2016","unstructured":"Kaul A, Gordon C, Crow MK, Touma Z, Urowitz MB, van Vollenhoven R, Ruiz-Irastorza G, Hughes G (2016) Systemic lupus erythematosus. Nat Rev Dis Primers 2:16039. https:\/\/doi.org\/10.1038\/nrdp.2016.39","journal-title":"Nat Rev Dis Primers"},{"key":"6155_CR17","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1111\/jth.13571","volume":"15","author":"M Scully","year":"2017","unstructured":"Scully M, Cataland S, Coppo P, de la Rubia J, Friedman KD, Kremer HJ, Lammle B, Matsumoto M, Pavenski K, Sadler E, Sarode R, Wu H (2017) Consensus on the standardization of terminology in thrombotic thrombocytopenic purpura and related thrombotic microangiopathies. J Thromb Haemost 15:312\u2013322. https:\/\/doi.org\/10.1111\/jth.13571","journal-title":"J Thromb Haemost"},{"key":"6155_CR18","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1093\/rheumatology\/keq395","volume":"50","author":"F Lansigan","year":"2011","unstructured":"Lansigan F, Isufi I, Tagoe CE (2011) Microangiopathic haemolytic anaemia resembling thrombotic thrombocytopenic purpura in systemic lupus erythematosus: the role of ADAMTS13. Rheumatology (Oxford) 50:824\u2013829. https:\/\/doi.org\/10.1093\/rheumatology\/keq395","journal-title":"Rheumatology (Oxford)"},{"key":"6155_CR19","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1056\/NEJMra1312353","volume":"371","author":"JN George","year":"2014","unstructured":"George JN, Nester CM (2014) Syndromes of thrombotic microangiopathy. N Engl J Med 371:654\u2013666. https:\/\/doi.org\/10.1056\/NEJMra1312353","journal-title":"N Engl J Med"},{"key":"6155_CR20","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1182\/blood-2018-02-791533","volume":"132","author":"C Masias","year":"2018","unstructured":"Masias C, Cataland SR (2018) The role of ADAMTS13 testing in the diagnosis and management of thrombotic microangiopathies and thrombosis. Blood 132:903\u2013910. https:\/\/doi.org\/10.1182\/blood-2018-02-791533","journal-title":"Blood"},{"key":"6155_CR21","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1159\/000441107","volume":"5","author":"A Sekine","year":"2015","unstructured":"Sekine A, Hasegawa E, Hiramatsu R, Mise K, Sumida K, Ueno T, Yamanouchi M, Hayami N, Suwabe T, Hoshino J, Sawa N, Takaichi K, Ohashi K, Fujii T, Ubara Y (2015) Two types of renovascular lesions in lupus nephritis with clinical thrombotic thrombocytopenic purpura. Case Rep Nephrol Dial 5:192\u2013199. https:\/\/doi.org\/10.1159\/000441107","journal-title":"Case Rep Nephrol Dial"},{"key":"6155_CR22","unstructured":"Niaz FA, Aleem A (2010) Response to rituximab in a refractory case of thrombotic thrombocytopenic purpura associated with systemic lupus erythematosus. Saudi J Kidney Dis Transpl 21:109\u2013112. http:\/\/sjkdt.org\/text.asp?2010\/21\/1\/109\/58783"},{"key":"6155_CR23","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1146\/annurev-immunol-042718-041717","volume":"38","author":"S Sakaguchi","year":"2020","unstructured":"Sakaguchi S, Mikami N, Wing JB, Tanaka A, Ichiyama K, Ohkura N (2020) Regulatory T cells and human disease. Annu Rev Immunol 38:541\u2013566. https:\/\/doi.org\/10.1146\/annurev-immunol-042718-041717","journal-title":"Annu Rev Immunol"},{"key":"6155_CR24","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1038\/s41590-018-0120-4","volume":"19","author":"M Dominguez-Villar","year":"2018","unstructured":"Dominguez-Villar M, Hafler DA (2018) Regulatory T cells in autoimmune disease. Nat Immunol 19:665\u2013673. https:\/\/doi.org\/10.1038\/s41590-018-0120-4","journal-title":"Nat Immunol"},{"key":"6155_CR25","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.3109\/0886022X.2014.934649","volume":"36","author":"H Huang","year":"2014","unstructured":"Huang H, Sun W, Liang Y, Long XD, Peng Y, Liu Z, Wen X, Jia M (2014) CD(+)(4)CD(+)(25) Treg cells in thrombotic thrombocytopenic purpura associated with systemic lupus erythematosus patients. Ren Fail 36:1263\u20131267. https:\/\/doi.org\/10.3109\/0886022X.2014.934649","journal-title":"Ren Fail"},{"key":"6155_CR26","doi-asserted-by":"publisher","first-page":"1628","DOI":"10.2215\/CJN.01480308","volume":"3","author":"H Wu","year":"2008","unstructured":"Wu H, Birmingham DJ, Rovin B, Hackshaw KV, Haddad N, Haden D, Yu CY, Hebert LA (2008) D-dimer level and the risk for thrombosis in systemic lupus erythematosus. Clin J Am Soc Nephrol 3:1628\u20131636. https:\/\/doi.org\/10.2215\/CJN.01480308","journal-title":"Clin J Am Soc Nephrol"},{"key":"6155_CR27","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1007\/s10067-013-2312-5","volume":"33","author":"H Jiang","year":"2014","unstructured":"Jiang H, An X, Li Y, Sun Y, Shen G, Tu Y, Tao J (2014) Clinical features and prognostic factors of thrombotic thrombocytopenic purpura associated with systemic lupus erythematosus: a literature review of 105 cases from 1999 to 2011. Clin Rheumatol 33:419\u2013427. https:\/\/doi.org\/10.1007\/s10067-013-2312-5","journal-title":"Clin Rheumatol"},{"key":"6155_CR28","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1097\/MOH.0000000000000602","volume":"27","author":"E Roose","year":"2020","unstructured":"Roose E, Veyradier A, Vanhoorelbeke K (2020) Insights into ADAMTS13 structure: impact on thrombotic thrombocytopenic purpura diagnosis and management. Curr Opin Hematol 27:320\u2013326. https:\/\/doi.org\/10.1097\/MOH.0000000000000602","journal-title":"Curr Opin Hematol"},{"key":"6155_CR29","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1016\/j.autrev.2014.01.004","volume":"13","author":"B Shenkman","year":"2014","unstructured":"Shenkman B, Einav Y (2014) Thrombotic thrombocytopenic purpura and other thrombotic microangiopathic hemolytic anemias: diagnosis and classification. Autoimmun Rev 13:584\u2013586. https:\/\/doi.org\/10.1016\/j.autrev.2014.01.004","journal-title":"Autoimmun Rev"},{"key":"6155_CR30","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.18040","author":"N Graca","year":"2022","unstructured":"Graca N, Joly BS, Voorberg J, Vanhoorelbeke K, Beranger N, Veyradier A, Coppo P (2022) TTP: from empiricism for an enigmatic disease to targeted molecular therapies. Br J Haematol. https:\/\/doi.org\/10.1111\/bjh.18040","journal-title":"Br J Haematol"},{"key":"6155_CR31","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1016\/j.ebiom.2018.12.035","volume":"40","author":"D Ramskold","year":"2019","unstructured":"Ramskold D, Parodis I, Lakshmikanth T, Sippl N, Khademi M, Chen Y, Zickert A, Mikes J, Achour A, Amara K, Piehl F, Brodin P, Gunnarsson I, Malmstrom V (2019) B cell alterations during BAFF inhibition with belimumab in SLE. EBioMedicine 40:517\u2013527. https:\/\/doi.org\/10.1016\/j.ebiom.2018.12.035","journal-title":"EBioMedicine"},{"key":"6155_CR32","doi-asserted-by":"publisher","first-page":"D10668","DOI":"10.1002\/14651858.CD010668.pub2","volume":"2","author":"JA Singh","year":"2021","unstructured":"Singh JA, Shah NP, Mudano AS (2021) Belimumab for systemic lupus erythematosus. Cochrane Database Syst Rev 2:D10668. https:\/\/doi.org\/10.1002\/14651858.CD010668.pub2","journal-title":"Cochrane Database Syst Rev"},{"key":"6155_CR33","doi-asserted-by":"publisher","first-page":"2328","DOI":"10.1002\/art.34400","volume":"64","author":"W Stohl","year":"2012","unstructured":"Stohl W, Hiepe F, Latinis KM, Thomas M, Scheinberg MA, Clarke A, Aranow C, Wellborne FR, Abud-Mendoza C, Hough DR, Pineda L, Migone TS, Zhong ZJ, Freimuth WW, Chatham WW (2012) Belimumab reduces autoantibodies, normalizes low complement levels, and reduces select B cell populations in patients with systemic lupus erythematosus. Arthritis Rheum 64:2328\u20132337. https:\/\/doi.org\/10.1002\/art.34400","journal-title":"Arthritis Rheum"},{"key":"6155_CR34","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1111\/cei.12472","volume":"179","author":"E Becerra","year":"2015","unstructured":"Becerra E, Scully MA, Leandro MJ, Heelas EO, Westwood JP, De La Torre I, Cambridge G (2015) Effect of rituximab on B cell phenotype and serum B cell-activating factor levels in patients with thrombotic thrombocytopenic purpura. CLIN EXP IMMUNOL 179:414\u2013425. https:\/\/doi.org\/10.1111\/cei.12472","journal-title":"CLIN EXP IMMUNOL"},{"key":"6155_CR35","first-page":"S120","volume":"34","author":"M Gerosa","year":"2016","unstructured":"Gerosa M, Gualtierotti R, Pisati M, Meroni PL (2016) Systemic lupus erythematosus complicated by thrombotic thrombocytopenic purpura. Clin Exp Rheumatol 34:S120\u2013S121","journal-title":"Clin Exp Rheumatol"},{"key":"6155_CR36","doi-asserted-by":"publisher","DOI":"10.1111\/1744-9987.13807","author":"JJ Tong","year":"2022","unstructured":"Tong JJ, Xiao H, Xu SQ (2022) A case report of systemic lupus erythematosus presented as thrombotic thrombocytopenic purpura and successfully treated with plasmapheresis and belimumab. Ther Apher Dial. https:\/\/doi.org\/10.1111\/1744-9987.13807","journal-title":"Ther Apher Dial"},{"key":"6155_CR37","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3324\/haematol.2019.s1","volume":"104","author":"R Woods","year":"2019","unstructured":"Woods R, Farland A, Owen J (2019) Abstract Book of Joint 10th BIC and 3rd INHIBITORS in Hemophilia International Conference Genoa, Italy, September 6\u20138 2019. Haematologica 104:1\u201344. https:\/\/doi.org\/10.3324\/haematol.2019.s1","journal-title":"Haematologica"},{"issue":"2006","key":"6155_CR38","doi-asserted-by":"publisher","first-page":"3993","DOI":"10.1182\/blood.V108.11.3993.3993","volume":"11","author":"SA Tulpule","year":"2006","unstructured":"Tulpule SA, Francis YA, Radia D, Harrison CN, Hunt BJ (2006) Safety and efficacy of mycophenolate mofetil in relapsing acquired thrombotic thrombocytopenic purpura: could it prevent further relapse? Blood 11(2006):3993. https:\/\/doi.org\/10.1182\/blood.V108.11.3993.3993","journal-title":"Blood"}],"container-title":["Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-022-06155-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10067-022-06155-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-022-06155-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,15]],"date-time":"2022-07-15T13:36:02Z","timestamp":1657892162000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10067-022-06155-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,7]]},"references-count":38,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2022,8]]}},"alternative-id":["6155"],"URL":"https:\/\/doi.org\/10.1007\/s10067-022-06155-6","relation":{},"ISSN":["0770-3198","1434-9949"],"issn-type":[{"value":"0770-3198","type":"print"},{"value":"1434-9949","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,7]]},"assertion":[{"value":"8 December 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 March 2022","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 March 2022","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 May 2022","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standard"}},{"value":"None.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosures"}}]}}